Inmune Bio, Inc.
INMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711754
No open-market purchases or sales by Inmune Bio, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $7.08M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Inmune Bio, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 33 | 2 | 34 | +3 |
| Shares | 1.92M | 152.1K | 1.65M | −115.4K (−6.5%) |
| Value | $11.9M | $943.0K | $10.4M | −$483.7K (−4.4%) |
2 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held Inmune Bio, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Financial Advocates Investment Management | 13,651 | $86.5K | 0.01% |
| Caption Management, LLC | 689 | $4.37K | 0.00% |
| Advisory Services Network, LLC | 90 | $571 | 0.00% |
| FMR LLC | 9 | $57 | 0.00% |
Sold out (1)
Institutions that held Inmune Bio, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| BNP Paribas Arbitrage, SA | 371 | $2.30K |
Not filed for Q4 2022 yet (2)
Institutions that held Inmune Bio, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| ACT Capital Management, LLC | 151,100 | $937.0K |
| Covington Capital Management | 1,000 | $6.00K |